AbbVie Set to Release Q1 Earnings Report Amid Stock Struggles
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ABBV?
Source: Fool
- Earnings Report Outlook: AbbVie is set to release its Q1 earnings report on April 29, with strong expectations for its key growth drugs Skyrizi and Rinvoq, projected to exceed $31 billion in annual sales by 2026, potentially providing a catalyst for stock recovery.
- Humira's Impact: While Humira remains AbbVie's third best-selling drug, its U.S. patent expiration in 2023 raises concerns about future performance; if other growth drivers fail to perform, the market may react negatively towards AbbVie.
- Declining Imbruvica Sales: AbbVie's cancer drug Imbruvica faces declining sales due to increased competition and government price negotiations, which could further reduce revenue; however, if the company meets or exceeds its projected $14.7 billion net revenue for the quarter, implying a 10% year-over-year growth, the stock could soar.
- Long-Term Investment Appeal: Despite short-term market volatility, AbbVie, as a pharmaceutical giant, offers consistent revenue and earnings, along with a remarkable dividend history of 54 consecutive annual increases, making it an attractive option for long-term income investors in the current economic climate.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 197.380
Low
223.00
Averages
252.00
High
289.00
Current: 197.380
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Q1 Earnings Expected to Show Recovery
- Earnings Growth Expectation: AbbVie is projected to report Q1 EPS growth of 8.5% year-over-year to $2.67, with revenue expected at $14.72 billion, reflecting a 10.3% increase, aligning with the company's own guidance and indicating a recovery in profitability.
- Long-Term Growth Drivers: Analysts believe that strong performances from Skyrizi and Rinvoq will offset the decline from Humira, with long-term earnings projections indicating a compound annual growth rate (CAGR) in the upper single digits, suggesting stable growth for the company moving forward.
- Sales Forecast: Management anticipates a total sales growth of 9.5% for the year, with net revenues around $67 billion, an adjusted gross margin exceeding 84%, and an adjusted operating margin ratio of approximately 48.5%, further solidifying the company's market position.
- Dividend Growth Recovery: Analysts noted that AbbVie's recent annual dividend increase of 5.48% suggests a stabilization in growth following a recent slowdown, enhancing investor confidence in the company's future prospects.
See More
AbbVie Set to Release Q1 Earnings Report Amid Stock Struggles
- Earnings Report Outlook: AbbVie is set to release its Q1 earnings report on April 29, with strong expectations for its key growth drugs Skyrizi and Rinvoq, projected to exceed $31 billion in annual sales by 2026, potentially providing a catalyst for stock recovery.
- Humira's Impact: While Humira remains AbbVie's third best-selling drug, its U.S. patent expiration in 2023 raises concerns about future performance; if other growth drivers fail to perform, the market may react negatively towards AbbVie.
- Declining Imbruvica Sales: AbbVie's cancer drug Imbruvica faces declining sales due to increased competition and government price negotiations, which could further reduce revenue; however, if the company meets or exceeds its projected $14.7 billion net revenue for the quarter, implying a 10% year-over-year growth, the stock could soar.
- Long-Term Investment Appeal: Despite short-term market volatility, AbbVie, as a pharmaceutical giant, offers consistent revenue and earnings, along with a remarkable dividend history of 54 consecutive annual increases, making it an attractive option for long-term income investors in the current economic climate.
See More
AbbVie Q1 Earnings Outlook and Growth Drivers
- Key Growth Drivers: AbbVie's Skyrizi and Rinvoq are projected to exceed $31 billion in annual sales by 2026, one year ahead of schedule, indicating strong market demand and the company's competitive edge in immunology.
- Humira Performance Concerns: Although Humira remains AbbVie's third best-selling drug, its loss of patent exclusivity in 2023 raises concerns about its future performance, potentially impacting investor confidence.
- Financial Expectations: AbbVie anticipates a net revenue of $14.7 billion for Q1, reflecting approximately 10% year-over-year growth; achieving this target could boost the company's stock price and enhance market confidence.
- Dividend Appeal: As a member of the
See More
Rinvoq Shows Superior Efficacy Over Humira in RA Study
- Clinical Trial Results: In the phase 3b/4 SELECT-SWITCH trial involving around 500 rheumatoid arthritis patients, 43.3% of those on Rinvoq achieved low disease activity by week 12, significantly outperforming the 22.4% seen with Humira, indicating a clear efficacy advantage for Rinvoq.
- Secondary Endpoint Achievement: Additionally, 28.4% of Rinvoq patients reached an even lower disease activity measure (DAS28-CRP<2.6), compared to just 14.5% for Humira, further validating Rinvoq's therapeutic potential in this patient population.
- Drug Class Comparison: As a JAK inhibitor, Rinvoq demonstrates superior efficacy over the TNF inhibitor Humira, particularly in patients who have failed TNF therapy, potentially providing AbbVie with a new growth avenue in a competitive biopharmaceutical market.
- Market Outlook: With Humira facing biosimilar competition, Rinvoq's strong performance not only enhances AbbVie's market position but also may drive future sales growth, particularly in the rheumatoid arthritis treatment sector.
See More
AbbVie Submits New Drug Application for Alopecia Treatment
- Clinical Trial Success: In the Phase 3 UP-AA clinical program, upadacitinib achieved the primary endpoint of a SALT score ≤ 20 at week 24, demonstrating significant efficacy that could potentially improve patients' quality of life and reshape treatment paradigms for severe alopecia areata.
- Hair Regrowth Breakthrough: Upadacitinib is the first JAK inhibitor to meet the ranked secondary endpoint of complete scalp hair regrowth (SALT = 0) at week 24, showcasing its unique advantages in treating alopecia, which may attract a larger patient base.
- Broad Patient Population: Approximately 51% of the 716 patients in the trial had a baseline SALT score ≥ 95, indicating near-total scalp hair loss, and the efficacy results of upadacitinib provide new hope for these patients, potentially driving significant market demand.
- Regulatory Review Underway: The safety and efficacy of upadacitinib are currently under regulatory review by the U.S. FDA and the European Medicines Agency, and if approved, it will open new market opportunities for AbbVie in the immunotherapy sector, further solidifying its industry position.
See More
AbbVie’s Rinvoq Outperforms Humira in Rheumatoid Arthritis Study
- Clinical Trial Success: AbbVie’s SELECT-SWITCH study demonstrated that Rinvoq outperformed Humira in treating adults with moderate to severe rheumatoid arthritis, successfully meeting its primary endpoint and showcasing significant superiority in achieving low disease activity.
- Efficacy Comparison Data: Approximately 43.3% of patients treated with Rinvoq achieved low disease activity compared to only 22.4% for Humira, indicating a clear competitive advantage for Rinvoq in terms of treatment efficacy.
- Safety Assessment: Both treatments showed no new safety concerns during the 12-week study period, further enhancing Rinvoq's market acceptance and patient confidence in its use.
- Positive Market Reaction: AbbVie shares rose over 1% in pre-market trading on Tuesday, reflecting investor optimism regarding the study results, which may drive further growth for the company in the rheumatoid arthritis market.
See More
AbbVie Q1 Earnings Expected to Show Recovery
- Earnings Growth Expectation: AbbVie is projected to report Q1 EPS growth of 8.5% year-over-year to $2.67, with revenue expected at $14.72 billion, reflecting a 10.3% increase, aligning with the company's own guidance and indicating a recovery in profitability.
- Long-Term Growth Drivers: Analysts believe that strong performances from Skyrizi and Rinvoq will offset the decline from Humira, with long-term earnings projections indicating a compound annual growth rate (CAGR) in the upper single digits, suggesting stable growth for the company moving forward.
- Sales Forecast: Management anticipates a total sales growth of 9.5% for the year, with net revenues around $67 billion, an adjusted gross margin exceeding 84%, and an adjusted operating margin ratio of approximately 48.5%, further solidifying the company's market position.
- Dividend Growth Recovery: Analysts noted that AbbVie's recent annual dividend increase of 5.48% suggests a stabilization in growth following a recent slowdown, enhancing investor confidence in the company's future prospects.
See More
AbbVie Set to Release Q1 Earnings Report Amid Stock Struggles
- Earnings Report Outlook: AbbVie is set to release its Q1 earnings report on April 29, with strong expectations for its key growth drugs Skyrizi and Rinvoq, projected to exceed $31 billion in annual sales by 2026, potentially providing a catalyst for stock recovery.
- Humira's Impact: While Humira remains AbbVie's third best-selling drug, its U.S. patent expiration in 2023 raises concerns about future performance; if other growth drivers fail to perform, the market may react negatively towards AbbVie.
- Declining Imbruvica Sales: AbbVie's cancer drug Imbruvica faces declining sales due to increased competition and government price negotiations, which could further reduce revenue; however, if the company meets or exceeds its projected $14.7 billion net revenue for the quarter, implying a 10% year-over-year growth, the stock could soar.
- Long-Term Investment Appeal: Despite short-term market volatility, AbbVie, as a pharmaceutical giant, offers consistent revenue and earnings, along with a remarkable dividend history of 54 consecutive annual increases, making it an attractive option for long-term income investors in the current economic climate.
See More
AbbVie Q1 Earnings Outlook and Growth Drivers
- Key Growth Drivers: AbbVie's Skyrizi and Rinvoq are projected to exceed $31 billion in annual sales by 2026, one year ahead of schedule, indicating strong market demand and the company's competitive edge in immunology.
- Humira Performance Concerns: Although Humira remains AbbVie's third best-selling drug, its loss of patent exclusivity in 2023 raises concerns about its future performance, potentially impacting investor confidence.
- Financial Expectations: AbbVie anticipates a net revenue of $14.7 billion for Q1, reflecting approximately 10% year-over-year growth; achieving this target could boost the company's stock price and enhance market confidence.
- Dividend Appeal: As a member of the
See More
Rinvoq Shows Superior Efficacy Over Humira in RA Study
- Clinical Trial Results: In the phase 3b/4 SELECT-SWITCH trial involving around 500 rheumatoid arthritis patients, 43.3% of those on Rinvoq achieved low disease activity by week 12, significantly outperforming the 22.4% seen with Humira, indicating a clear efficacy advantage for Rinvoq.
- Secondary Endpoint Achievement: Additionally, 28.4% of Rinvoq patients reached an even lower disease activity measure (DAS28-CRP<2.6), compared to just 14.5% for Humira, further validating Rinvoq's therapeutic potential in this patient population.
- Drug Class Comparison: As a JAK inhibitor, Rinvoq demonstrates superior efficacy over the TNF inhibitor Humira, particularly in patients who have failed TNF therapy, potentially providing AbbVie with a new growth avenue in a competitive biopharmaceutical market.
- Market Outlook: With Humira facing biosimilar competition, Rinvoq's strong performance not only enhances AbbVie's market position but also may drive future sales growth, particularly in the rheumatoid arthritis treatment sector.
See More
AbbVie Submits New Drug Application for Alopecia Treatment
- Clinical Trial Success: In the Phase 3 UP-AA clinical program, upadacitinib achieved the primary endpoint of a SALT score ≤ 20 at week 24, demonstrating significant efficacy that could potentially improve patients' quality of life and reshape treatment paradigms for severe alopecia areata.
- Hair Regrowth Breakthrough: Upadacitinib is the first JAK inhibitor to meet the ranked secondary endpoint of complete scalp hair regrowth (SALT = 0) at week 24, showcasing its unique advantages in treating alopecia, which may attract a larger patient base.
- Broad Patient Population: Approximately 51% of the 716 patients in the trial had a baseline SALT score ≥ 95, indicating near-total scalp hair loss, and the efficacy results of upadacitinib provide new hope for these patients, potentially driving significant market demand.
- Regulatory Review Underway: The safety and efficacy of upadacitinib are currently under regulatory review by the U.S. FDA and the European Medicines Agency, and if approved, it will open new market opportunities for AbbVie in the immunotherapy sector, further solidifying its industry position.
See More
AbbVie’s Rinvoq Outperforms Humira in Rheumatoid Arthritis Study
- Clinical Trial Success: AbbVie’s SELECT-SWITCH study demonstrated that Rinvoq outperformed Humira in treating adults with moderate to severe rheumatoid arthritis, successfully meeting its primary endpoint and showcasing significant superiority in achieving low disease activity.
- Efficacy Comparison Data: Approximately 43.3% of patients treated with Rinvoq achieved low disease activity compared to only 22.4% for Humira, indicating a clear competitive advantage for Rinvoq in terms of treatment efficacy.
- Safety Assessment: Both treatments showed no new safety concerns during the 12-week study period, further enhancing Rinvoq's market acceptance and patient confidence in its use.
- Positive Market Reaction: AbbVie shares rose over 1% in pre-market trading on Tuesday, reflecting investor optimism regarding the study results, which may drive further growth for the company in the rheumatoid arthritis market.
See More
